Please login to the form below

Not currently logged in
Email:
Password:

Konstantin Linnik to head IP strategy at Idea Pharma

Former senior corporate counsel at Pfizer joins clinical stage strategy consultancy as general counsel and principal IP strategist

Konstantin Linnik - Idea PharmaIdea Pharma has appointed former senior corporate counsel at Pfizer Konstantin Linnik as its general counsel and principal intellectual property (IP) strategist.

Idea, which specialises in advising a company's strategy at the phase II stage of development, said Linnink will lead IP inputs into whole product design, giving insight into the potential opportunities for early phase assets and advising on how to improve developmental products.

The appointment is also expected to expand Idea's portfolio of clients to medium-sized pharma companies, and also give the company a base in Boston, US.

Linnik, who will join from Boston law firm Nutter McClennen and Fish LLP, said Idea's focus on distinct elements such as IP during early phase development influenced his decision to join the company.

He said: “A small change in product concept, that produces a better medicine, one with even six months more protection, can make billions of dollars difference over the lifecycle.”

Mike Rea, CEO of Idea, said: “The fantastic thing about Konstantin is that he gets it - that the role of invention isn't over when someone comes up with a pathway and a molecule.”

20th December 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics